OncoMatch/Clinical Trials/NCT05879250
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Is NCT05879250 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies STAT3 Inhibitor WP1066 for glioblastoma, idh-wildtype.
Treatment: STAT3 Inhibitor WP1066 — This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: MGMT unmethylated
Prior therapy
Cannot have received: investigational agent
Receipt of investigational agents within =< 2 weeks prior to registration
Cannot have received: gene therapy
Prior receipt of gene therapy, at any time
Cannot have received: (bevacizumab)
Prior receipt of bevacizumab, at any time
Cannot have received: (Gliadel)
Prior receipt of Gliadel, at any time
Cannot have received: (Optune)
Exception: Patients who can safely discontinue Optune prior to initiating trial therapy may participate
Patients who are on active therapy with Optune and who are unable to safely discontinue Optune prior to initiating trial therapy
Cannot have received: anti-cancer therapy
Exception: Patients who discontinue anti-cancer therapy prior to initiating trial therapy may participate
Patients who are on active therapeutic anti-cancer therapy and who are unable to discontinue the anti-cancer therapy prior to initiating trial therapy
Lab requirements
Blood counts
WBC >= 3.0 x 10^9/L; ANC >= 1.0 x 10^9/L; Platelet count >= 75 x 10^9/L (within <= 30 days prior to registration, without growth factor support and/or receipt of blood products within <= 14 days prior to testing)
Kidney function
Creatinine or creatinine clearance within normal institutional limits. If creatinine above institutional normal, CrCl >= 60 mL/min/1.73 m^2 (within <= 30 days prior to registration, Cockcroft-Gault formula)
Liver function
Total bilirubin <= 1.5 x ULN or direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 x ULN; AST <= 2.5 x ULN; ALT <= 2.5 x ULN (within <= 30 days prior to registration)
Cardiac function
Corrected QT (QTc) B interval < 450 ms
WBC >= 3.0 x 10^9/L ... Platelet count >= 75 x 10^9/L ... Total bilirubin <= 1.5 x ULN ... AST <= 2.5 x ULN ... ALT <= 2.5 x ULN ... Creatinine or creatinine clearance within normal institutional limits ... INR <= 1.5 x ULN or for subjects receiving anticoagulant therapy, INR must be within the therapeutic range ... aPTT <= 1.5 x ULN or for subjects receiving anticoagulant therapy, aPTT must be within the therapeutic range ... Corrected QT (QTc) B interval < 450 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern University · Chicago, Illinois
- Northwestern Medicine: Warrenville · Warrenville, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify